Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
Jazz Pharmaceuticals plc incurred term loan of $201,909,488.38 aggregate principal amount of additional Tranche B-1 Dollar Term Loans maturing May 5, 2028.
- Instrument
- term loan
- Principal
- $201,909,488.38 aggregate principal amount of additional Tranche B-1 Dollar Term Loans
- Maturity
- May 5, 2028
- Event
- incurrence
Exact text from the filing
Jazz Lux borrowed $201,909,488.38 aggregate principal amount of additional Tranche B-1 Dollar Term Loans
View on SEC.gov
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
Jazz Pharmaceuticals plc amended credit facility with Bank of America, N.A. at Term SOFR plus 3.00% (with a floor of 0.50%) or the prime lending rate plus 2.00.
- Instrument
- credit facility
- Counterparty
- Bank of America, N.A.
- Rate
- Term SOFR plus 3.00% (with a floor of 0.50%) or the prime lending rate plus 2.00
- Event
- amendment
Exact text from the filing
The applicable margin for the Tranche B-1 Dollar Term Loans is 3.00% (in the case of Term SOFR borrowings) and 2.00% (in the case of borrowings at the prime lending rate), a decrease of 50 basis points from the applicable margin on the Initial Dollar Term Loans
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Jazz Pharmaceuticals plc amended Repricing Amendment with Bank of America, N.A., as administrative agent and U.S. Bank Trust Company, National Association, as collateral trustee (effective 2024-01-19).
- Action
- amendment
- Agreement
- credit facility
- Counterparty
- Bank of America, N.A., as administrative agent and U.S. Bank Trust Company, National Association, as collateral trustee
- Effective
- 2024-01-19
Exact text from the filing
abilité limitée ) incorporated and existing under the laws of Luxembourg (“Jazz Lux”) and wholly owned subsidiary of Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in Ireland (the “Company”), entered into an amendment (the “Repricing Amendment”) to the Credit Agreement, dated May 5, 2021, by and among Jazz Lux and certain other subsidiaries of the Company, as borrowers (collectively with the Company and Jazz Lux, the “Borrowers”), the lenders and issuing banks from time to time party thereto, Bank of America, N.A., as administrative agent and U.S.
View on SEC.gov